MDNAF (Medicenna Therapeutics) Total Debt per Share: $0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDNAF Medicenna Therapeutics Corp MDNAF
29 GF Score
Price $0.32
! 1 Warning Sign
View Full Analysis

What is Medicenna Therapeutics Total Debt per Share?

Medicenna Therapeutics MDNAF 29 Total Debt per Share is $0.00 as of Mar. 2026. GuruFocus rates MDNAF with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

$0.00 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Medicenna Therapeutics's Total Debt Per Share for the quarter that ended in Mar. 2026 was $0.00.

Medicenna Therapeutics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Medicenna Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicenna Therapeutics Total Debt per Share Chart

Medicenna Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medicenna Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MDNAF
29GF Score
Medicenna Therapeutics Corp MDNAF
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicenna Therapeutics Total Debt per Share Calculation

Medicenna Therapeutics's Total Debt Per Share for the fiscal year that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.04+0.05)/83.42
=0.00

Medicenna Therapeutics's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.04+0.05)/83.42
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.00 mean?
Medicenna Therapeutics (MDNAF) has a Total Debt per Share of $0.00 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Medicenna Therapeutics and its competitors.
Is Medicenna Therapeutics' Total Debt per Share too high?
Medicenna Therapeutics' current Total Debt per Share is $0.00. Overall, Medicenna Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Medicenna Therapeutics' Total Debt per Share compare to VRTX and REGN?
Medicenna Therapeutics' Total Debt per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Medicenna Therapeutics and its competitors. Medicenna Therapeutics's current Total Debt per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicenna Therapeutics stock overvalued right now?
Medicenna Therapeutics (MDNAF) has a current Total Debt per Share of $0.00. The current Total Debt per Share is $0.00. Medicenna Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Medicenna Therapeutics (MDNAF), the current Total Debt per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicenna Therapeutics Business Description

Other Exchanges MDNA:Canada
Address 2 Bloor Street West, Suite 903, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
29GF Score

Get the complete analysis for MDNAF

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price